New drug cocktail shows promise for multiple myeloma patients
NCT ID NCT04653246
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests whether adding the investigational drug isatuximab to a standard four-drug combination can improve treatment response in people newly diagnosed with multiple myeloma. About 52 adults aged 75 or younger who need treatment will receive the combination before a stem cell transplant. The main goal is to see how many achieve a very good partial response or better after two treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.